1. Metabolic Syndrome and Benign Prostatic Enlargement: A Systematic Review and Meta-Analysis
  2. Personalized Medicine for Management of Benign Prostatic Hyperplasia
  3. Treatment Satisfaction with Tadalafil or Tamsulosin versus Placebo in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results from a Randomized, Placebo-controlled Study
  4. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study
  5. Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia
  6. Benign Prostatic Hyperplasia: Prostatic Arterial Embolization versus Transurethral Resection of the Prostate-A Prospective, Randomized, and Controlled Clinical Trial
  7. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia
  8. Benign prostatic hyperplasia: a new metabolic disease?
  9. Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil
  10. Progression of Lower Urinary Tract Symptoms After Discontinuation of 1 Medication From 2-Year Combined Alpha-blocker and 5-Alpha-reductase Inhibitor Therapy for Benign Prostatic Hyperplasia in Men - A Randomized Multicenter Study
  11. The Fluctuation of Nocturia in Men with Lower Urinary Tract Symptoms Allocated to Placebo during a 12-Month Randomized, Controlled Trial
  12. Tadalafil - a therapeutic option in the management of BPH-LUTS
  13. Early Symptom Improvement and Discontinuation of 5-?-Reductase Inhibitor (5ARI) Therapy in Patients With Benign Prostatic Hyperplasia (BPH)
  14. Association of Alpha-Blockers and 5-Alpha Reductase Inhibitors in Benign Prostatic Hyperplasia With Fractures: A Meta-analysis and Systematic Review of the Literature
  15. Risk of acute myocardial infarction after transurethral resection of prostate in elderly
  16. Study of Quality of life in Patients with Benign Prostatic Hyperplasia under Treatment with Silodosin
  17. BiVap Saline Vaporization of the Prostate in Men With Benign Prostatic Hyperplasia: Our Clinical Experience
  18. Prostate-Specific Antigen Evolution After Photoselective Vaporization of the Prostate
  19. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
  20. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
  21. Early Symptom Improvement and Discontinuation of 5-?-Reductase Inhibitor (5ARI) Therapy in Patients With Benign Prostatic Hyperplasia (BPH)
  22. Evaluation of the effect of sildenafil and/or doxazosin on Benign prostatic hyperplasia-related lower urinary tract symptoms and erectile dysfunction
  23. A Retrospective Evaluation of Benign Prostatic Hyperplasia Treatment by Transurethral Vaporization Using a 1470?nm Laser
  24. Association of Alpha-Blockers and 5-Alpha Reductase Inhibitors in Benign Prostatic Hyperplasia With Fractures: A Meta-analysis and Systematic Review of the Literature
  25. Study of Quality of life in Patients with Benign Prostatic Hyperplasia under Treatment with Silodosin
  26. The effect of combined therapy with tamsulosin hydrochloride and meloxicam in patients with benign prostatic hyperplasia symptoms and impact on nocturia and sleep quality
  27. Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
  28. Treatment Patterns in Alpha-Blocker Therapy for Benign Prostatic Hyperplasia
  29. Cost-effectiveness analysis at 2 years of surgical treatment of benign prostatic hyperplasia by photoselective vaporization of the prostate with GreenLight-Photo vaporization 120W versus transurethral resection of the prostate
  30. Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms
  31. Dutasteride on Benign Prostatic Hyperplasia: A Meta-analysis on Randomized Clinical Trials in 6460 Patients
  32. What's truly minimally invasive in benign prostatic hyperplasia surgery?
  33. Association of Metabolic Syndrome and Benign Prostatic Hyperplasia in Chinese Patients of Different Age Decades
  34. Extraperitoneal Laparoscopic Adenomectomy (Madigan) versus Bipolar Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia Greater than 80 ml: Complications and Functional Outcomes after 3-Year Follow-up
  35. Muscarinic receptor subtype mRNA expression in the human prostate: association with age, pathological diagnosis, prostate size, or potentially interfering medications?
  36. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
  37. Effectiveness of Tadalafil 5?mg Once Daily in the Treatment of Men with Lower Urinary Tract Symptoms Suggestive to Benign Prostatic Hyperplasia With or Without Erectile Dysfunction: Results from Naturalistic Observational TadaLutsEd Study
  38. 180 W vs 120 W Lithium Triborate Photoselective Vaporization of the Prostate for Benign Prostatic Hyperplasia: A Global, Multicenter Comparative Analysis of Perioperative Treatment Parameters
  39. Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies
  40. Effect of estimated prostate volume on silodosin-mediated improvements in the signs and symptoms of BPH: does prostate size matter?
  41. Management of benign prostatic hyperplasia with silodosin
  42. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
  43. Early Results from a United States Trial of Prostatic Artery Embolization in the Treatment of Benign Prostatic Hyperplasia
  44. A hybrid fuzzy-ontology based intelligent system to determine level of severity and treatment recommendation for Benign Prostatic Hyperplasia
  45. Effects of low-dose tamsulosin on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia
  46. 5?-reductase type 3 enzyme in benign and malignant prostate
  47. Twelve-Month Follow-up Results of Photoselective Vaporization of the Prostate With a 980-nm Diode Laser for Treatment of Benign Hyperplasia
  48. Non-invasive urodynamics predicts outcome prior to surgery for prostatic obstruction
  49. The use of PDE-5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
  50. A Comparative Randomized Prospective Study to Evaluate Efficacy and Safety of Combination of Tamsulosin and Tadalafil vs. Tamsulosin or Tadalafil Alone in Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
  51. Actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia: temporal trends of prescription and hospitalization rates over 5 years in a large population of Italian men
  52. Comparing the effectiveness of intranasal desmopressin and doxazosin in men with nocturia: a pilot randomized clinical trial
  53. Relationship of Estimated Glomerular Filtration Rate With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Measures in Middle-aged Men With Moderate to Severe Lower Urinary Tract Symptoms
  54. Canadian trend in surgical management of benign prostatic hyperplasia and laser therapy from 2007-2008 to 2011-2012
  55. Lack of association between the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphism and the risk of benign prostatic hyperplasia in Caucasian men
  56. Safety and efficiency of thulium laser prostate resection for the treatment of benign prostatic hyperplasia in large prostates
  57. Technical Aspects of Holmium Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia
  58. Obesity Is Associated With Larger Prostate Volume but not With Worse Urinary Symptoms: Analysis of a Large Multiethnic Cohort
  59. Prostate volume correlates with diabetes in elderly benign prostatic hyperplasia patients
  60. Prostate-specific antigen mass and free prostate-specific antigen mass for predicting the prostate volume of korean men with biopsy-proven benign prostatic hyperplasia
  61. Photoselective vaporization for the treatment of benign prostatic hyperplasia
  62. Use of selenium-silymarin mix reduces lower urinary tract symptoms and prostate specific antigen in men
  63. Renal capsule xenografting and subcutaneous pellet implantation for the evaluation of prostate carcinogenesis and benign prostatic hyperplasia
  64. A Retrospective Review of Office-based 532-nm Greenlight Laser Prostatectomy in Men With Symptomatic Benign Prostatic Hyperplasia
  65. A Good Alternative to Indwelling Catheter Owing to Benign Prostate Hyperplasia in Elderly: Memotherm Prostatic Stent
  66. Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study
  67. Urolift®, a new minimally invasive treatment for patients with low urinary tract symptoms secondary to BPH. Preliminary results
  68. Current evaluation and treatment of nocturia
  69. White blood cell count is positively associated with benign prostatic hyperplasia
  70. Comparison of 7 ?1-adrenoceptor Antagonists in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia:A Short-term Crossover Study
  71. Development of a Doxazosin and Finasteride Transdermal System for Combination Therapy of Benign Prostatic Hyperplasia
  72. HMGB1: A potential target for treatment of benign prostatic hyperplasia
  73. Clinical implications of a feeling of incomplete emptying with little post-void residue in men with lower urinary tract symptoms
  74. Prostate stem cells in the development of benign prostate hyperplasia and prostate cancer: emerging role and concepts
  75. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction
  76. The impact of obesity on benign and malignant urologic conditions
  77. Vitamin D and benign prostatic hyperplasia - a review
  78. Diagnosis of Bladder Outlet Obstruction in Men Using a Near-infrared Spectroscopy Instrument as the Noninvasive Monitor for Bladder Function
  79. Are Transrectal Prostate Biopsies Routinely Indicated in Patients with Incidentally Diagnosed Prostate Cancer following Transurethral Resection of the Prostate for Benign Disease
  80. Increased population use of medications for male lower urinary tract symptoms/benign prostatic hyperplasia correlates with changes in indications for transurethral resection of the prostate
  81. Does Polyvinyl Alcohol Particle Size Change the Outcome of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia? Results from a Single-center Randomized Prospective Study
  82. Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction
  83. A randomized trial comparing thulium laser resection to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: four-year follow-up results
  84. Impacts of Histological Prostatitis on Sexual Function and Lower Urinary Tract Symptoms in Patients With Benign Prostatic Hyperplasia
  85. Hyperglycemia, Hyperinsulinemia, Insulin Resistance, and the Risk of BPH/LUTS Severity and Progression Over Time in Community Dwelling Black Men: The Flint Men's Health Study
  86. Promising Molecular Targets and Biomarkers for Male BPH and LUTS
  87. Pathogenic mechanisms linking benign prostatic hyperplasia, lower urinary tract symptoms and erectile dysfunction
  88. A randomized trial comparing thulium laser resection to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: four-year follow-up results
  89. Impacts of Histological Prostatitis on Sexual Function and Lower Urinary Tract Symptoms in Patients With Benign Prostatic Hyperplasia
  90. Hyperglycemia, Hyperinsulinemia, Insulin Resistance, and the Risk of BPH/LUTS Severity and Progression Over Time in Community Dwelling Black Men: The Flint Men's Health Study
  91. Promising Molecular Targets and Biomarkers for Male BPH and LUTS
  92. Urine flow acceleration is superior to Qmax in diagnosing BOO in patients with BPH
  93. Targeting Stromal Androgen Receptor Suppresses Prolactin-Driven Benign Prostatic Hyperplasia (BPH)
  94. Prostatic Artery Embolization for Enlarged Prostates Due to Benign Prostatic Hyperplasia. How I Do It
  95. Transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement: a quality and meta-analysis
  96. Preoperative factors affecting postoperative early quality of life during the learning curve of holmium laser enucleation of the prostate
  97. A Randomized Trial Comparing Diode Laser Enucleation of the Prostate with Plasmakinetic Enucleation and Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia
  98. PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH
  99. Efficacy and Safety of Tadalafil 5 mg Once Daily for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Subgroup Analyses of Pooled Data From 4 Multinational, Randomized, Placebo-controlled Clinical Studies
  100. Age-related changes in the innervation of the prostate gland: Implications for prostate cancer initiation and progression
  101. The Relationship Between Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and the Number of Components of Metabolic Syndrome
  102. Penetration depth with the XPS Greenlight ® laser assessed by contrast enhanced ultrasound
  103. Holmium; YAG TUIP (transurethral incision of the prostate) vs. green light (532-nm-laser) PVP (photoselective vaporization of the prostate) for treatment of BPH (benign prostatic hyperplasia) less than 40ml; Long-term evaluation
  104. Transurethral resection of prostate abscess: is it different from conventional transurethral resection for benign prostatic hyperplasia?
  105. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: Prospective pressure-flow study
  106. AIM2, an interferon-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer
  107. Severity Profiles in Patients Diagnosed of Benign Prostatic Hyperplasia in Spain
  108. Cost-effectiveness of dutasteride-tamsulosin combination therapy for the treatment of symptomatic benign prostatic hyperplasia: A Canadian model based on the CombAT trial
  109. A Report on Major Complications and Biochemical Recurrence After Primary and Salvage Cryosurgery for Prostate Cancer in Patients With Prior Resection for Benign Prostatic Hyperplasia: A Single-center Experience
  110. Comparing the Immunoexpression of FUT3 and FUT6 between Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia
  111. Quantitative Iodine-Based Material Decomposition Images with Spectral CT Imaging for Differentiating Prostatic Carcinoma from Benign Prostatic Hyperplasia
  112. Interaction Study Between Finasteride and Tamsulosin in Healthy Young Male Subjects
  113. Resident training in urology: Bipolar transurethral resection of the prostate - a safe method in learning endoscopic surgical procedure
  114. Comparative randomized study on the efficaciousness of endoscopic bipolar prostate resection versus monopolar resection technique. 3 year follow-up
  115. Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis
  116. Inhibition of androgen induces autophagy in benign prostate epithelial cells
  117. Should Modest Elevations in Prostate-Specific Antigen, International Prostate Symptom Score, or Their Rates of Increase Over Time be Used as Surrogate Measures of Incident Benign Prostatic Hyperplasia?
  118. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment
  119. Differentiation of central gland prostate cancer from benign prostatic hyperplasia using monoexponential and biexponential diffusion-weighted imaging
  120. Urethral Lift for Benign Prostatic Hyperplasia: A Comprehensive Review of the Literature
  121. Two Laser Ablation Techniques for a Prostate Less Than 60 mL: Lessons Learned 70 Months After a Randomized Controlled Trial
  122. Transurethral enucleation and resection of the prostate vs transvesical prostatectomy for prostate volumes >80?mL: a prospective randomized study
  123. Review of current laser therapies for the treatment of benign prostatic hyperplasia
  124. Effects of Tadalafil on Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia and on Erectile Dysfunction in Sexually Active Men with Both Conditions: Analyses of Pooled Data from Four Randomized, Placebo-Controlled Tadalafil Clinical Studies
  125. Which Laser Works Best for Benign Prostatic Hyperplasia?
  126. Significant decrease of extracellular matrix in prostatic urethra of patients with benign prostatic hyperplasia
  127. Multi-Center Randomized Controlled Blinded Study of the Prostatic Urethral Lift for the Treatment of LUTS Associated with Prostate Enlargement Due to BPH: The L.I.F.T. Study
  128. The effects of chlormadinone acetate on lower urinary tract symptoms and erectile functions of patients with benign prostatic hyperplasia: a prospective multicenter clinical study
  129. Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer
  130. Stromal response to prostate cancer: nanotechnology-based detection of thioredoxin-interacting protein partners distinguishes prostate cancer associated stroma from that of benign prostatic hyperplasia
  131. Enablers and barriers affecting medication-taking behaviour in aging men with benign prostatic hyperplasia
  132. Dutasteride for the treatment of benign prostatic hyperplasia
  133. Qianliening capsule treats benign prostatic hyperplasia via suppression of the EGF/STAT3 signaling pathway
  134. Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial
  135. Effect of Selective Alpha-blocker Tamsulosin on Erectile Function in Patients With Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
  136. The histology of prostate tissue following prostatic artery embolization for the treatment of benign prostatic hyperplasia
  137. Steroidal 5?-reductase and 17?-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases
  138. Action Mechanism of Ginkgo biloba Leaf Extract Intervened by Exercise Therapy in Treatment of Benign Prostate Hyperplasia
  139. Effects of Serenoa Repens, Selenium and Lycopene (Profluss®) on chronic inflammation associated with Benign Prostatic Hyperplasia: results of ?FLOG? (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study
  140. Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia
  141. Evaluation and validation of the Core Lower Urinary Tract Symptom Score as an outcome assessment tool for the treatment of benign prostatic hyperplasia: Effects of the ?1-adrenoreceptor antagonist silodosin
  142. Phosphodiesterase inhibitors in clinical urology
  143. The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia
  144. Effect of Transurethral Resection of the Prostate on Storage Symptoms in Patients with Benign Prostatic Hyperplasia of Less than 30 ml
  145. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH)
  146. Relationship between Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Metabolic Syndrome in Korean Men
  147. Relationship Between Predictors of the Risk of Clinical Progression of Benign Prostatic Hyperplasia and Metabolic Syndrome in Men With Moderate to Severe Lower Urinary Tract Symptoms
  148. Can 80 W KTP Laser Vaporization Effectively Relieve the Obstruction in Benign Prostatic Hyperplasia?: A Nonrandomized Trial
  149. Prevalence of Benign Prostatic Hyperplasia on Jeju Island: Analysis from a Cross-sectional Community-based Survey
  150. Strong impact of nocturia on sleep quality in patients with lower urinary tract symptoms
  151. uPA/PAI-1 ratios distinguish benign prostatic hyperplasia and prostate cancer
  152. Electroacupuncture for moderate and severe benign prostatic hyperplasia: a randomized controlled trial
  153. The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses
  154. A cost-minimisation analysis comparing photoselective vaporisation (PVP) and transurethral resection of the prostate (TURP) for the management of symptomatic benign prostatic hyperplasia (BPH) in Queensland, Australia
  155. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study
  156. Urinary prostate-specific antigen: predictor of benign prostatic hyperplasia progression?
  157. A cost-minimisation analysis comparing photoselective vaporisation (PVP) and transurethral resection of the prostate (TURP) for the management of symptomatic benign prostatic hyperplasia (BPH) in Queensland, Australia
  158. Comparison of Fluid Absorption between Transurethral Enucleation and Transurethral Resection for Benign Prostate Hyperplasia
  159. Androgen Receptor Roles in the Development of Benign Prostate Hyperplasia (BPH)
  160. The role of naftopidil in the management of benign prostatic hyperplasia
  161. Prostatitis - Diagnosis and treatment
  162. Relationship of postoperative recatheterization and intraoperative bladder distention volume in holmium laser enucleation of the prostate for benign prostatic hyperplasia
  163. The Prostate Cancer Patient Had Higher C-Reactive Protein Than BPH Patient
  164. Effect of patient-optimized doses of tamsulosin on erectile function in men with erectile dysfunction and lower urinary tract symptoms
  165. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: A prospective randomized trial
  166. Age-stratified outcomes of holmium laser enucleation of the prostate
  167. Tadalafil: A Phosphodiesterase-5 Inhibitor for Benign Prostatic Hyperplasia
  168. Postoperative infectious complications in our early experience with holmium laser enucleation of the prostate for benign prostatic hyperplasia
  169. Differential Adoption of Laser Prostatectomy for Treatment of Benign Prostatic Hyperplasia
  170. Active Surveillance of Very-low-risk Prostate Cancer in the Setting of Active Treatment of Benign Prostatic Hyperplasia With 5?-reductase Inhibitors
  171. Predictors of Successful First-line Antimuscarinic Monotherapy in Men With Enlarged Prostate and Predominant Storage Symptoms
  172. Biexponential Apparent Diffusion Coefficients Values in the Prostate: Comparison among Normal Tissue, Prostate Cancer, Benign Prostatic Hyperplasia and Prostatitis
  173. Noninvasive methods to evaluate bladder obstruction in men
  174. SRD5A1 and SRD5A2 are Associated with the Treatment for Benign Prostatic Hyperplasia with the Combination of 5?-reductase Inhibitors and ?-adrenergic-receptor Antagonist
  175. Transurethral resection of the prostate in kidney transplant recipients: urological and renal functional outcomes at long-term follow-up
  176. Prevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS)
  177. Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate
  178. Preneoplasia in the prostate gland with emphasis on high grade prostatic intraepithelial neoplasia
  179. Applicators for Magnetic Resonance-Guided Ultrasonic Ablation of Benign Prostatic Hyperplasia
  180. Expression analysis of Thrombospondin 2 in prostate cancer and benign prostatic hyperplasia
  181. Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases - a medium term, prospective, randomized comparison
  182. Holmium Laser Enucleation of the Prostate for Persistent Lower Urinary Tract Symptoms After Prior Benign Prostatic Hyperplasia Surgery
  183. Management of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia in Real-life Practice in France: A Comprehensive Population Study
  184. Quality of Life and Clinical Symptom Improvement Support Prostatic Artery Embolization for Patients with Acute Urinary Retention Caused by Benign Prostatic Hyperplasia
  185. Vitamin D receptor as a therapeutic target for benign prostatic hyperplasia
  186. Serenoa Repens, Lycopene and Selenium: A Triple Therapeutic Approach to Manage Benign Prostatic Hyperplasia
  187. GreenLight XPS 180W vs HPS 120W Laser Therapy for Benign Prostate Hyperplasia: A Prospective Comparative Analysis After 200 Cases in a Single-center Study
  188. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates
  189. Development of a quality of life scale specific for patients with benign prostatic hyperplasia
  190. Thulium Laser Enucleation Versus Plasmakinetic Resection of the Prostate: A Randomized Prospective Trial With 18-Month Follow-up
  191. Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up
  192. The impact of metabolic syndrome on the responsiveness to ?1-blocker in men with BPH/LUTS
  193. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms
  194. Long-term effects of doxazosin, finasteride, and combination therapy on quality of life in men with benign prostatic hyperplasia
  195. Risk Factors for Failure of Early Catheter Removal After Greenlight HPS Laser Photoselective Vaporization Prostatectomy in Men With Benign Prostatic Hyperplasia
  196. Effect of photoselective vaporization prostatectomy on lower urinary tract symptoms in benign prostatic hyperplasia with or without intravesical prostatic protrusion
  197. Effects of Hyaluronic Acid and Carboxymethylcellulose on Urethral Stricture After Transurethral Resections of the Prostate for Benign Prostatic Hyperplasia: A Multicenter, Single Blinded, Randomized Controlled Study
  198. Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist
  199. Cost-effectiveness of single-dose tamsulosin and dutasteride combination therapy compared with tamsulosin monotherapy in patients with benign prostatic hyperplasia in the UK
  200. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials
  201. Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: retrospective analysis
  202. Expression and localization of aquaporins in benign prostate hyperplasia and prostate cancer
  203. Qianliening capsule treats benign prostatic hyperplasia via induction of prostatic cell apoptosis
  204. The Prognostic Use of Inflammation and Tissue Necrosis in Benign Prostatic Hyperplasia
  205. Relationship between endothelial dysfunction and nocturia with benign prostatic hyperplasia
  206. Investigational therapies targeted to the treatment of benign prostatic hyperplasia
  207. Tadalafil Once Daily Improves Ejaculatory Function, Erectile Function, and Sexual Satisfaction in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Erectile Dysfunction: Results from a Randomized, Placebo- and Tamsulosin-Controlled, 12-Week Double-Blind Study
  208. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan
  209. Retrospective study of laparoscopic radical prostatectomy for localized prostate cancer after transurethral resection of the prostate compared with retropubic radical prostatectomy at the same institution
  210. The effect of first dose of tamsulosin on flow rate and its predictive ability on the improvement of LUTS in men with BPH in the mid-term
  211. Treatment of lower urinary tract symptoms: Agents for intraprostatic injection
  212. Retinoic Acid Receptor ?2 (RAR?2): Nonivasive Biomarker for Distinguishing Malignant versus Benign Prostate Lesions from Bodily Fluids
  213. Standard surgical treatment for benign prostatic hyperplasia is safe for patients over 75 years: analysis of 100 cases from a high-volume urologic center
  214. Improvement of erectile function in patients with benign prostatic hyperplasia undergoing transurethral plasmakinetic resection of the prostate
  215. Efficacy and safety of the simultaneous administration of mirodenafil and an ?-blocker in men with BPH-LUTS: a multicenter open-label prospective study
  216. Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia Patients: Orchestrated by Chronic Prostatic Inflammation and Prostatic Calculi
  217. Meriva®, a lecithinized curcumin delivery system, in the control of benign prostatic hyperplasia: a pilot, product evaluation registry study
  218. Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it
  219. Body Mass Index Predicts Failure of Surgical Management in Benign Prostatic Hyperplasia
  220. Benign Prostatic Hyperplasia and its Treatment: Impact on Quality of Life and Sexual Function
  221. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians
  222. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized multicenter study
  223. Prostatic Arterial Embolization for Benign Prostatic Hyperplasia: Short- and Intermediate-term Results
  224. Nutrition and benign prostatic hyperplasia
  225. Androgen receptor GGC polymorphism and testosterone levels associated with high risk of prostate cancer and benign prostatic hyperplasia
  226. Hormonal manipulation of benign prostatic hyperplasia
  227. Current status of brachytherapy for prostate cancer
  228. Simultaneous transurethral resection of bladder cancer and prostate may reduce recurrence rates: A systematic review and meta-analysis
  229. A Prospective, Randomized Clinical Trial Comparing Plasmakinetic Resection of the Prostate with Holmium Laser Enucleation of the Prostate Based on a 2-Year Followup
  230. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation
  231. Prostate cancer incidence and tumor severity in Georgia: descriptive epidemiology, racial disparity, and geographic trends
  232. Association between DNA methylation of HSPB1 and death in low Gleason score prostate cancer
  233. Treatment satisfaction with low-dose tamsulosin for symptomatic benign prostatic hyperplasia: results from a multicentre cross-sectional survey
  234. Establishing the clinical and economic benefits of adherence to 5-alpha reductase inhibitors in benign prostatic hyperplasia: an assessment of Medicare and Medicaid patients
  235. The link between benign prostatic hyperplasia and prostate cancer
  236. Correlation between benign prostatic hyperplasia and inflammation
  237. Determination of tamsulosin in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study
  238. Prospective, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Phase IIb Clinical Trial of the Pore-Forming Protein PRX302 for Targeted Treatment of Symptomatic Benign Prostatic Hyperplasia
  239. Does benign prostatic hyperplasia treatment with alpha-blockers affect prostate cancer risk?
  240. Bipolar versus Monopolar Transurethral Resection of the Prostate: Results of a Comparative, Prospective Bicenter Study - Perioperative Outcome and Long-Term Efficacy
  241. Learning Curve for Bipolar Transurethral Enucleation and Resection of the Prostate in Saline for Symptomatic Benign Prostatic Hyperplasia: Experience in the First 100 Consecutive Patients
  242. Genetic Sequence Variants Are Associated With Both Severity Of Lower Urinary Tract Symptoms And Prostate Cancer Susceptibility
  243. Imaging in benign prostatic hyperplasia: what is new?
  244. New emerging technologies in benign prostatic hyperplasia
  245. Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia
  246. Plasmakinetic Enucleation versus Bipolar Transurethral Resection of the Prostate for Prostates Larger than 70ml: a Prospective, Randomised Trial with 5-Year Follow-up
  247. Thulium Laser Vaporesection Versus Transurethral Electrovaporization of the Prostate in High-Risk Patients with Benign Prostatic Hyperplasia
  248. Adherence to 5-alpha reductase inhibitor therapy for benign prostatic hyperplasia: clinical and economic outcomes
  249. Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
  250. Overview of interventional treatment options for benign prostatic hyperplasia
  251. LUTS and Sleep Disorders: Emerging Risk Factor
  252. Noninvasive urodynamic evaluation
  253. Thulium laser vaporesection versus standard transurethral resection of the prostate: A randomized trial with transpulmonary thermodilution hemodynamic monitoring
  254. Associations Between Improvements in Lower Urinary Tract Symptoms and Sleep Disturbance Over Time in the CAMUS Trial
  255. Benign prostatic hyperplasia and lower urinary tract symptom guidelines
  256. A Randomized Double-blind Placebo-controlled Phase 2 Dose-ranging Study of OnabotulinumtoxinA in Men with Benign Prostatic Hyperplasia
  257. Emerging therapies: what's new is old and what's old is new
  258. Incidence of and risk factors for symptomatic benign prostatic hyperplasia in kidney transplant recipients: A cohort study
  259. Incidence and risk of treatment for benign prostatic hyperplasia in Japanese men: A 15-year longitudinal community-based study
  260. Efficacy and safety of bipolar plasma vaporization of the prostate with
  261. Prospective Short-Term Evaluation of Transurethral Needle Ablation Procedure in an Ambulatory Setting
  262. Remodeling of the muscle layer (detrusor muscle) of hyperactive bladder disease in patients with benign prostatic hyperplasia
  263. A comparative study of thulium laser resection of the prostate and bipolar transurethral plasmakinetic prostatectomy for treating benign prostatic hyperplasia
  264. What is significant hematuria for the primary care physician?
  265. Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial
  266. Benign prostatic hyperplasia (BPH) management in the primary care setting
  267. The application of 120-W high-performance system GreenLight laser vaporization of the prostate in high-risk patients
  268. Mid term outcomes of initial 250 case experience with GreenLight 120W-HPS photoselective vaporization prostatectomy for benign prostatic hyperplasia: comparison of prostate volumes < 60 cc, 60 cc-100 cc and > 100 cc
  269. Transurethral Resection of Prostate and the Role of Pharmacological Treatment with Dutasteride in Decreasing Surgical Blood Loss
  270. Acute urinary retention increases the risk of complications after transurethral resection of the prostate: a population-based study
  271. A 5-year retrospective analysis of 5?-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride
  272. Efficacy and safety of orally disintegrating tamsulosin tablets in Taiwanese patients with benign prostatic hyperplasia
  273. Phytotherapy in Urology. Current Scientific Evidence of its Application in Benign Prostatic Hyperplasia and Prostate Adenocarcinoma
  274. Update on the Sexual Impact of Treatment for Benign Prostatic Hyperplasia
  275. Safety and Toxicity of Saw palmetto in the Complementary and Alternative Medicine for Urological Symptoms (CAMUS) Trial
  276. Can We Predict the Outcome of 532 nm Laser Photoselective Vaporization of the Prostate? Time to Event Analysis
  277. Office Evaluation of Male Patients with Lower Urinary Tract Symptoms
  278. Development and optimization of multiparticulate drug delivery system of alfuzosin hydrochloride
  279. Population Based Trends in the Surgical Treatment of Benign Prostatic Hyperplasia
  280. Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia
  281. The impact of urinary incontinence of the lives of wives of men with incontinence: an integrative review
  282. High-intensity diode laser in combination with bipolar transurethral resection of the prostate: A new strategy for the treatment of large prostates (>80?ml)
  283. The Mechanism of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
  284. Tadalafil : In the Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia with or without Erectile Dysfunction
  285. Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia
  286. Tadalafil : In the Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia with or without Erectile Dysfunction
  287. High-intensity diode laser in combination with bipolar transurethral resection of the prostate: A new strategy for the treatment of large prostates (>80?ml)
  288. The Mechanism of Action of Phosphodiesterase Type 5 Inhibitors in the Treatment of Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
  289. Cholinergic drugs for treatment of recurrent urinary retention in high surgical risk/elderly BPH patients. A pilot study
  290. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo- and tamsulosin-controlled 12-week study in Asian men
  291. A multiscale, mechanism-driven, dynamic model for the effects of 5?-reductase inhibition on prostate maintenance
  292. Microwave thermotherapy for benign prostatic hyperplasia
  293. Age-related changes in prostate zonal volumes as measured by high-resolution magnetic resonance imaging (MRI): a cross-sectional study in over 500 patients
  294. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure
  295. Bipolar Transurethral Resection of the Prostate Causes Deeper Coagulation Depth and Less Bleeding Than Monopolar Transurethral Prostatectomy
  296. Botulinum neurotoxin type a for the treatment of benign prostatic hyperplasia: randomized study comparing two doses
  297. ?1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study
  298. Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia
  299. A comparison of virtual touch tissue quantification and digital rectal examination for discrimination between prostate cancer and benign prostatic hyperplasia
  300. Assessment of the Effect of Mirodenafil on the Hemodynamics of Healthy Male Korean Volunteers Administered Tamsulosin: A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study
  301. Intra-prostatic UroLift(®) implants for benign prostatic hyperplasia: Preliminary results of the four first cases performed in France
  302. Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia:preliminary results with a newly purified neurotoxin
  303. Various treatment options for benign prostatic hyperplasia: A current update
  304. Acetylcholine for Male LUTS
  305. Comparison of transurethral enucleation with bipolar and transurethral resection in saline for managing benign prostatic hyperplasia
  306. Phosphodiesterase Type 5 Inhibition Reverts Prostate Fibroblast-To-Myofibroblast Trans-Differentiation
  307. Activation of innate anti-viral immune response genes in symptomatic benign prostatic hyperplasia
  308. Content validity of the Benign Prostatic Hyperplasia Impact Index (BII); a measure of how urinary trouble and problems associated with BPH may impact the patient
  309. Effects of selenium status, dietary glucosinolate intake and serum glutathione S-transferase ? activity on the risk of benign prostatic hyperplasia
  310. Relationship between Intravesical Prostatic Protrusion and Postoperative Outcomes in Patients with Benign Prostatic Hyperplasia
  311. Relationship between Intravesical Prostatic Protrusion and Postoperative Outcomes in Patients with Benign Prostatic Hyperplasia
  312. Dietary supplements for benign prostatic hyperplasia: An overview of systematic reviews
  313. Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin
  314. Targeting Androgen Receptor to Suppress Macrophage-induced EMT and Benign Prostatic Hyperplasia (BPH) Development
  315. Urodynamic Effects of Transrectal Intraprostatic Ona botulinum Toxin A Injections for Symptomatic Benign Prostatic Hyperplasia
  316. Inhaled Anticholinergic Agents and Acute Urinary Retention in Men with Lower Urinary Tract Symptoms or Benign Prostatic Hyperplasia (September)
  317. Bladder Wall Thickness is Associated with Responsiveness of Storage Symptoms to Alpha-Blockers in Men with Lower Urinary Tract Symptoms
  318. Influence of intravesical prostatic protrusion on preoperative lower urinary tract symptoms and outcomes after 120 w high performance system laser treatment in men with benign prostatic hyperplasia
  319. Resistive Index of Prostate Capsular Arteries: A Newly Identified Parameter to Diagnose and Assess Bladder Outlet Obstruction in Patients with Benign Prostatic Hyperplasia
  320. Solifenacin Plus Tamsulosin Combination Treatment in Men With Lower Urinary Tract Symptoms and Bladder Outlet Obstruction: A Randomized Controlled Trial
  321. Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia
  322. Benign Prostatic Hyperplasia: Implications for Pharmacologic Treatment and Perioperative Care
  323. Comparation of the predictive value between ultrasonography and urodynamics for the efficacy of transurethral resection of prostate in benign prostatic hyperplasia patients
  324. Photoselective Vaporization of the Prostate with GreenLight HPS 120-W Laser for Benign Prostatic Hyperplasia: 36 Months' Follow-Up
  325. Is increased prostatic urethral angle related to lower urinary tract symptoms in males with benign prostatic hyperplasia/lower urinary tract symptoms?
  326. Incidence and Progression of Lower Urinary Tract Symptoms in a Large Prospective Cohort of United States Men
  327. Dutasteride, who is it more effective for? Second to fourth digit ratio and the relationship with prostate volume reduction by dutasteride treatment
  328. Two-year Outcome of High-risk Benign Prostate Hyperplasia Patients Treated With Transurethral Prostate Resection by Plasmakinetic or Conventional Procedure
  329. Association between physical activity, lower urinary tract symptoms (LUTS) and prostate volume
  330. Null genotypes at the GSTM1 and GSTT1 genes and the risk of benign prostatic hyperplasia: A case-control study and a meta-analysis
  331. Indications For and Use of Nonsteroidal Antiinflammatory Drugs and the Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial
  332. Change in intraoperative rectal temperature influencing erectile dysfunction following transurethral resection of the prostate
  333. Postoperative Outcomes of Plasmakinetic Transurethral Resection of the Prostate Compared to Monopolar Transurethral Resection of the Prostate in Patients with Comorbidities
  334. Analysis of Predictive Factors of Success for Prostate Photovaporization in Benign Prostatic Hyperplasia by Greenlight Laser
  335. Preperitoneal Single-port Transvesical Enucleation of the Prostate (STEP) for Large-volume BPH: One-year Follow-up of Qmax, IPSS, and QoL
  336. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study
  337. 5?-Reductases in Human Physiology: An Unfolding Story
  338. Clinical and safety profiles of bipolar transurethral vaporization of the prostate in saline: A preliminary report
  339. Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: Long-term results from the combination of dutasteride and tamsulosin study
  340. A novel equation and nomogram including body weight for estimating prostate volumes in men with biopsy-proven benign prostatic hyperplasia
  341. Importance of Relieving the Most Bothersome Symptom for Improving Quality of Life in Male Patients With Lower Urinary Tract Symptoms
  342. Association of Angiotensin I Converting Enzyme Polymorphism as Genetic Risk Factor in Benign Prostatic Hyperplasia and Prostate Cancer
  343. Prostatic hyperplasia is highly associated with nocturia and excessive sleepiness: a cross-sectional study
  344. Impact of preoperative therapy with 5-a-reductase inhibitors in the treatment of benign prostatic hyperplasia
  345. Evaluative Care Guideline Compliance Is Associated With Provision of Benign Prostatic Hyperplasia Surgery
  346. Robot-assisted simple prostatectomy (RASP): does it make sense?
  347. Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: A systematic review
  348. Interventional therapies for lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)
  349. Real-World Use of Permixon® in Benign Prostatic Hyperplasia - Determining Appropriate Monotherapy and Combination Treatment
  350. Photoselective Vaporisation of the Prostate Using 80-W and 120-W Laser Versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: A Systematic Review with Meta-Analysis from 2002 to 2012
  351. Botulinum toxin injection for lower urinary tract dysfunction
  352. Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review
  353. Transitional Zone Index and Intravesical Prostatic Protrusion in Benign Prostatic Hyperplasia Patients: Correlations according to Treatment Received and Other Clinical Data
  354. Comparison between prostate volume and intravesical prostatic protrusion in detecting bladder outlet obstruction due to benign prostatic hyperplasia
  355. Examining the 'gold standard': a comparative critical analysis of three consecutive decades of monopolar transurethral resection of the prostate (TURP) outcomes
  356. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000-2008)
  357. Prevalence and Correlates of Nocturia in Community-dwelling Older Men: Results from the Korean Longitudinal Study on Health and Aging
  358. Dutasteride/Tamsulosin: in benign prostatic hyperplasia
  359. ?-Blocker Monotherapy and ?-Blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years' Long-Term Results
  360. Trends and attitudes in surgical management of benign prostatic hyperplasia
  361. Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial
  362. Effects of Interview Mode on Assessments of Erectile and Ejaculatory Dysfunction among Men with Benign Prostatic Hyperplasia (BPH)
  363. Transurethral vapor enucleation and resection of prostate with plasma vaporization button electrode for the treatment of benign prostatic hyperplasia: a feasibility study
  364. A Randomized, Placebo-Controlled Study to Assess Safety and Efficacy of Vardenafil 10?mg and Tamsulosin 0.4?mg vs. Tamsulosin 0.4?mg Alone in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
  365. A Review of Animal and Human Studies for Management of Benign Prostatic Hyperplasia with Natural Products; Perspective of new Pharmacological Agents
  366. Optimizing the management of benign prostatic hyperplasia
  367. Photoselective vaporization versus transurethral resection of the prostate for benign prostatic hyperplasia : a meta-analysis
  368. Increased infiltrated macrophages in benign prostatic hyperplasia (BPH): the role of stromal androgen receptor in macrophage-induced prostate stromal cell proliferation
  369. The Potential Role of a Self-Management Intervention for Benign Prostate Hyperplasia
  370. Consensus on the Clinical Impact of the New Scientific Evidence Available on Benign Prostatic Hyperplasia
  371. Transurethral Bipolar Plasmakinetic Resection Combined with 2??m Continuous Wave Laser Vaporization: A New Method for the Treatment of Large Volume Benign Prostatic Hyperplasia
  372. Does prostate configuration affect the efficacy and safety of GreenLight HPS™ laser photoselective vaporization prostatectomy (PVP)?
  373. Effects of Flavocoxid, a Dual Inhibitor of Cyclooxygenase and 5-Lipoxygenase Enzymes, on Benign Prostatic Hyperplasia
  374. Finasteride Reduces the Risk of Incident Clinical Benign Prostatic Hyperplasia
  375. A report from the 27th Annual Congress of the European Association of Urology (February 24-28, 2012 - Paris, France)
  376. Chronic urinary retention in men: How we define it, and how does it affect treatment outcome
  377. Effectiveness of medical and surgical therapies for lower urinary tract symptoms in the community setting
  378. Benign prostatic hyperplasia: from bench to clinic
  379. Efficacy and safety of tamsulosin for treating lower urinary tract symptoms associated with benign prostatic hyperplasia: a multicenter, randomized, controlled, open-label non-inferiority study
  380. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities
  381. Non-steroidal anti-inflammatory drug use and the risk of benign prostatic hyperplasia-related outcomes and nocturia in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial
  382. Changes in Initial Expenditures for Benign Prostatic Hyperplasia Evaluation in the Medicare Population: A Comparison to Overall Medicare Inflation
  383. Can we identify men who will have complications from benign prostatic obstruction (BPO)?: ICI-RS 2011
  384. Quantifying the Contribution of Symptom Improvement to Satisfaction of Men With Moderate to Severe Benign Prostatic Hyperplasia: 4-Year Data From the CombAT Trial
  385. Combination Pharmacological Therapies for the Management of Benign Prostatic Hyperplasia
  386. iTRAQ Identification of Candidate Serum Biomarkers Associated with Metastatic Progression of Human Prostate Cancer
  387. Holmium Laser Enucleation of the Prostate: A Modified Enucleation Technique and Initial Results
  388. Rapid ambulatory pathway laser prostatectomy is safe: results within the global period
  389. 160-Watt Lithium Triboride Laser Vaporization Versus Transurethral Resection of Prostate: A Prospective Nonrandomized Two-center Trial
  390. Efficacy of alpha blocker treatment according to the degree of intravesical prostatic protrusion detected by transrectal ultrasonography in patients with benign prostatic hyperplasia
  391. Transversal European survey on testosterone deficiency diagnosis
  392. A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with ?-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
  393. Longitudinal Changes of Benign Prostate-specific Antigen and [-2]Proprostate-specific Antigen in Seven Years in a Community-based Sample of Men
  394. Effect of testosterone supplementation with and without a dual 5?-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial
  395. Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication
  396. Surgical management of benign prostatic hyperplasia by thermotherapy and other emerging techniques: A review of the literature by the LUTS committee of the French Urological Association
  397. Association between lower urinary tract symptoms and sexual dysfunction assessed using the core lower urinary tract symptom score and International index of erectile function-5 questionnaires
  398. Surgical management of benign prostatic hyperplasia by endoscopic techniques using electricity and open prostatectomy: A review of the literature by the LUTS committee of the French Urological Association
  399. Regulation of cell proliferation through a KIT-mediated mechanism in benign prostatic hyperplasia
  400. IPSS quality of life question: a possible indicator of depression among patients with lower urinary tract symptoms
  401. Do men with prostate abnormalities (prostatitis/benign prostatic hyperplasia/prostate cancer) develop immunity to spermatozoa or seminal plasma?
  402. Do men with prostate abnormalities (prostatitis/benign prostatic hyperplasia/prostate cancer) develop immunity to spermatozoa or seminal plasma?
  403. Holmium laser enucleation of the prostate technique for benign prostatic hyperplasia
  404. Monotherapy with Tadalafil or Tamsulosin Similarly Improved Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia in an International, Randomised, Parallel, Placebo-Controlled Clinical Trial
  405. Impact of changing trends in medical therapy on surgery for benign prostatic hyperplasia over two decades
  406. Diet, Obesity, and Prostate Health: Are We Missing the Link?
  407. Population Based Comparative Effectiveness of Transurethral Resection of the Prostate and Laser Therapy for Benign Prostatic Hyperplasia
  408. Hemodynamic Effects of Once-daily Tadalafil in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant ?(1)-Adrenergic Antagonist Therapy: Results of a Multicenter Randomized, Double-Blind, Placebo-controlled Trial
  409. Robotic single port suprapubic transvesical enucleation of the prostate (R-STEP): initial experience
  410. Robotic Simple Prostatectomy: Multi-Institutional Outcomes for Glands Larger than 100 gm
  411. Combining Growth Hormone-Releasing Hormone Antagonist With Luteinizing Hormone-Releasing Hormone Antagonist Greatly Augments Benign Prostatic Hyperplasia Shrinkage
  412. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and antimuscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder
  413. 180-W XPS GreenLight Laser Therapy for Benign Prostate Hyperplasia: Early Safety, Efficacy, and Perioperative Outcome After 201 Procedures
  414. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia
  415. American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited
  416. Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men
  417. Role of Inflammation in Benign Prostatic Hyperplasia
  418. Prostatic Urethral Lift: Two-year Results After Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
  419. Diabetes Treatment and Progression of Benign Prostatic Hyperplasia in Community-dwelling Black and White Men
  420. 120 W Greenlight HPS Laser Photoselective Vaporization of the Prostate for Treatment of Benign Prostatic Hyperplasia in Men with Detrusor Underactivity
  421. Elective hemi transurethral resection of prostate: a safe and effective method of treating huge benign prostatic hyperplasia
  422. Correlations Among Cardiovascular Risk Factors, Prostate Blood Flow, and Prostate Volume in Patients With Clinical Benign Prostatic Hyperplasia
  423. GreenLight HPS™ 120-W laser vaporization vs transurethral resection of the prostate (<60?mL): a 2-year randomized double-blind prospective urodynamic investigation
  424. Potassium-titanyl-phosphate laser photoselective vaporisation for benign prostatic hyperplasia: 5 year follow-up from a District General Hospital
  425. prostatic hyperplasia
  426. Benign Prostate Specific Antigen Distribution and Associations With Urological Outcomes in Community Dwelling Black and White Men
  427. Potassium-titanyl-phosphate laser vaporisation of the prostate: A case series of an unusual complication
  428. A Study Comparing Plasmakinetic Enucleation to Bipolar Plasmakinetic Resection of the Prostate for Benign Prostatic Hyperplasia
  429. Is There a Relationship Between Bladder Outlet Obstruction due to Benign Prostatic Hyperplasia and Pulmonary Thromboembolism?
  430. Influences of neuroregulatory factors on the development of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction in aging men
  431. The Correlation Between Metabolic Syndrome and Prostatic Diseases
  432. Revival of thermotherapy for benign prostatic hyperplasia
  433. Panurethral Stricture after Photovaporization of the Prostate for Benign Prostatic Hyperplasia
  434. Initial Experiences with a 980 nm Diode Laser for Photoselective Vaporization of the Prostate for the Treatment of Benign Prostatic Hyperplasia
  435. Dietary patterns and prostatic diseases
  436. Comparative Analysis of the Efficacy and Safety of Conventional Transurethral Resection of the Prostate, Transurethral Resection of the Prostate in Saline (TURIS), and TURIS-Plasma Vaporization for the Treatment of Benign Prostatic Hyperplasia: A Pilot Study
  437. Does age affect the efficacy and safety of GreenLight HPS(™) laser photoselective vaporization prostatectomy?
  438. American Urological Association and European Association of Urology guidelines in the management of benign prostatic hypertrophy: revisited
  439. Transurethral resection of prostate with plasmakinetic energy: 100 months results of a prospective randomized trial
  440. Can noninvasive evaluation of benign prostatic obstruction be optimized?
  441. Outline of JUA clinical guidelines for benign prostatic hyperplasia
  442. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen
  443. ?-Blockers for benign prostatic hyperplasia: the new era
  444. Differential Expression of the Androgen-Conjugating UGT2B15 and UGT2B17 Enzymes in Prostate Tumor Cells during Cancer Progression
  445. A multicentre single-blind randomized controlled trial comparing bipolar and monopolar transurethral resection of the prostate
  446. Long-term followup after electrocautery transurethral resection of the prostate for benign prostatic hyperplasia
  447. Recent advances in the surgical treatment of benign prostatic hyperplasia
  448. Preservation of Sexual Function with the Prostatic Urethral Lift: A Novel Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
  449. Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue
  450. Estimation of clinically significant prostate volumes by digital rectal examination: a comparative prospective study
  451. Quartz Head Contact Laser Fiber: A Novel Fiber for Laser Ablation of the Prostate Using the 980 nm High Power Diode Laser
  452. Prescriber Monitoring for Benign Prostatic Hyperplasia Within a Family Medicine Clinic: A Comparison of Medication Classes
  453. Benign prostatic hyperplasia medical treatment: Systematic review of the literature by the CTMH/AFU